Pamela, Shamela, and the Politics of the Pamela Vogue
There are Swarms of Moral Romances. One, of late Date, divided the World into such opposite Judgments, that some extolled it to the Stars, whilst others treated it with Contempt. Whence arose, particularly among the Ladies, two different Parties, Pamelists and Antiparnelists. ... Some look upon this young Virgin as an Example for Ladies to follow; nay, there have been those, who did not scruple to recommend this Romance from the Pulpit. Others, on the contrary, discover in it, the Behaviour of an hypocritical, crafty Girl, in her Courtship; who understands the Art of bringing a Man to her Lure.'
"A Sawce-box and Boldface Indeed": Refiguring the Female Servant in the Pamela-Antipamela Debate
Shortly before Pamela's marriage to Mr. B in Richardson's first novel, Mrs. Jewkes tells Pamela that she should alter her style of address to Mr. B and desist from calling him "master." The once-assertive Pamela now demurely answers, "He shall always be my Master; and I shall think myself more and more his Servant."1 This remark and others like it elicit from most feminist critics a quizzically-arched eyebrow as it becomes clear that Pamela's potentially revolutionary class ascent paradoxically entails greater subordination from her as a wife to her husband than was required from a servant by her master. Expressing a view often repeated by subsequent critics, Terry
Botulinum toxin in the management of chronic migraine: clinical evidence and experience
Chronic migraine (CM) is a severely disabling neurological condition characterized by episodes of pulsating unilateral or bilateral headache. The United States Food and Drug Administration (FDA) approved onabotulinumtoxinA (Botox®) for the prophylactic treatment of CM in 2010. It has been shown that onabotulinumtoxinA is effective in the reduction of headache frequency and severity in patients with CM. Treatment is well tolerated by the patients. This review reports on the history of botulinum neurotoxin (BoNT) in CM and presents the current clinical evidence for the use of onabotulinumtoxinA in the treatment of CM.